Core Insights - Rami Elghandour, President of Arcellx, sold 89,916 shares for approximately $10.24 million on February 27, 2026, as per SEC Form 4 filing [1][2] - The company is set to be acquired by Gilead Sciences for an estimated $7.8 billion, with Gilead purchasing Arcellx at $115 per share and a contingent value right of $5 per share [6] - Arcellx has made significant advancements in its clinical-stage projects, including a multiple myeloma treatment progressing to Phase 2 development and a blood cancer immunotherapy awaiting FDA approval [7] Transaction Summary - Shares sold (direct): 89,916 [2] - Transaction value: $10.2 million [2] - Post-transaction shares (direct): 276,051 [2] - Post-transaction shares (indirect): 416,500 [2] - Post-transaction value (direct ownership): approximately $31.41 million [2] Company Overview - Current stock price: $113.79 [4] - Market capitalization: $6.65 billion [4] - Net loss (TTM): -$228.93 million [4] - 1-year price change: 75.55% [4] Company Snapshot - Arcellx, Inc. is a clinical-stage biotechnology company focused on innovative immunotherapies for cancer and other incurable diseases, primarily working with oncology healthcare providers and patients in the U.S. and select global markets [5] Insider Activity - Elghandour's recent sale of 89,916 shares is significantly larger than his historical median sell size of 38,300 shares since January 2025 [8] - After the sale, Elghandour retains 276,051 shares in direct ownership and maintains 416,500 shares indirectly through a spousal trust, indicating continued material exposure to Arcellx equity [8] Future Prospects - If the treatment for multiple myeloma proves successful, it could become a major product in the healthcare space and a significant revenue generator for Arcellx [9] - The impending merger raises questions about the timeline for investors to trade shares before the company is delisted [9]